News

Boston Scientific plans to launch the Taxus Liberte stent in early November 2008 in the US, following completion of the introduction of its Taxus Express(2) Atom paclitaxel-eluting coronary

Catena is claimed to be the first and only approved therapy in Canada to treat this devastating genetic disorder. Santhera estimates that there are a few hundred Friedreich’s

This important approval provides these patients with the only factor VIII treatment that the FDA has determined safe and effective for routine prophylaxis – a treatment regimen recommended

The results demonstrate the product has an excellent safety profile and shows promising signs of efficacy, as indicated by a reduction in lung inflammation, the company said. The

The centerpiece of the collaboration effort will be the development of Tripos’s new Muse de novo design product, which is targeted for commercial release in the fourth quarter

The new drug application (NDA) was filed on June 29, 2007 following the results from a randomized, placebo controlled, Phase III clinical trial in 209 subjects who met

Under the terms of the agreement, Cenomed acquired from TorreyPines Therapeutics the worldwide development rights to three compounds, phenserine, Posiphen and bisnorcymcerine, for chemical defense and counterterrorism defense.

The expansion phase of the study allows the clinical sites to enroll additional patients meeting the enrollment criteria to evaluate safety and efficacy across a range of related

The licensing agreement provides Pharmacells access to Moraga’s proprietary adult stem cell technology for banking its blastomere-like stem cells (BLSCs) that have been isolated, processed, and cryopreserved from